1. Mohamed L. Sorror, MD, MSc ASH Oral presentation December 2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study
Mohamed L. Sorror, MD, MSc
ASH Oral presentation December 2018

2. Introduction
Population-based studies also indicate overall improvement in survival of older (60-80 years old) AML patients
(Bower, Blood Cancer Journal, 2016)
Only a small minority (6%-8%) of them receive HCT (Medeiros, Ann Hematol. 2015).
Prospective multi-center longitudinal study
First presentation of adults with AML to treatment
Compared survival according to whether or not pts received HCT at later time points

5. Results Median follow-up = 16.8 months (range, 0.1–52.4)
2-years survival rate after HCT: 58%
In the unadjusted model, a survival advantage was associated with receiving allogeneic HCT compared with no transplantation, P =
The survival advantage for allogeneic HCT was observed in patients with intermediate (P = ) or unfavorable (P < ) ELN risk and in vulnerable patients (P < ) 
In the adjusted model for AML- and patient-specific variables, there was no survival benefit observed for allogeneic HCT, P = 0.21

7. Conclusion
Adjusting for key AML-specific and pt-specific variables negated the observed benefit of HCT over non-HCT therapies in reducing mortality rates among AML pts.
Results might reflect
1) improvement in supportive care and non-HCT therapies
2) a relatively high non-relapse mortality early after HCT and the need for longer follow-up to demonstrate an adjusted benefit of HCT
3) the high selectivity of the transplant eligibility process, as we accounted here for variables that are often ignored in “genetic assignment” randomized studies (i.e. comorbidities and function).
New randomized trials are needed